rtsky777

📱Open Assets--Contracts--Today’s Realized Profit and Loss--Funding Fees and Trading Fees-Total Trading Fees📲$BNB .
Like I just played for a month and had nearly 600U in fees, if activated, there’s a 150 oil rebate.
If you filled in the invitation code when registering, then you’re good, that means you have a fee rebate, just find your contact person. If there’s no fee rebate, then this fee is charged by the exchange.
If you wrote my invitation code while playing on Binance, the 100 oil fee can legally refund up to 25 oil to yourself.
Registration invitation code is 1053575781
Contract activation invitation code is 1053951016
If you have to spend, save what you can 👍👍👍

I watched the match between Portugal and Croatia from start to finish this morning.
I was deeply moved after watching. In the added time, as the referee's clock was ticking down, the Croatian players refused to give up. They kept pressing hard to score. Even though in the end the goal was ruled offside, the score finished 2–1. It still moved me a lot.
This style of playing football is just like trading in my contract. Refuse to give up—when it looks like you're about to get liquidated, I was still mature and calm, and added margin. In the end, though, I still got liquidated.

Is there a brother or sister exchange lately that’s been pulling a mouse?
Look at how down-and-out I am...
Please, just give me a mouse to draw~$AAPL.US $NVDA.US

Daily One Unpopular Cold Hot US Stock
$FDMT
【My View】A biotech company specializing in ophthalmic gene therapy in the late-stage clinical phase. Its core product, 4D-150, has entered global Phase 3 trials. Over the next one and a half years, it is likely to see multiple major data catalysts. This is a typical data-driven investment target, suitable for trading based on clinical progress and debate, not suitable for heavy long-term holding.
Key Data
Stock price: $13.00, up 2.44% on the day. Intraday high: $13.40, low: $12.63.
Market cap: Approximately $695 million.
Cash on the balance sheet: As of the end of 2025, cash, cash equivalents, and marketable securities are about $514 million. Management expects the funds to support operations through the second half of 2028.
30-day average daily trading value: About $13 million. Liquidity is average; it is a mid-to-small cap biotech.
Short interest data: As of mid-May 2026, short interest is about 12.08 million shares, with a short ratio of about 25%. Days to cover: 19.1 days. If subsequent clinical data exceed expectations, a Short Squeeze situation cannot be ruled out.
My Reasoning
The company focuses on ophthalmic AAV gene therapy. Its core product, 4D-150, targets large-market diseases such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). The goal is to maintain efficacy while reducing the frequency of patients’ intravitreal injection visits, leaving a broad market opportunity.
Current progress of 4D-150 is exceeding expectations:
✅ The global Phase 3 trial 4FRONT-1 has completed patient enrollment ahead of schedule;
✅ The global Phase 3 trial 4FRONT-2 also completed enrollment about four months early, indicating smooth clinical execution.
The company has sufficient cash reserves, with relatively low near-term financing pressure. Going forward, stock-price drivers will come more from clinical data rather than financial performance.
⚠️ Potential Risks
The biggest risk for biotech still comes from clinical trials.
If PRISM or subsequent Phase 3 results show efficacy and safety do not meet market expectations, the stock price may experience significant volatility.
In addition, the ophthalmology space is highly competitive. Large pharma companies such as Regeneron and Roche have also developed related products. Even if approvals come later, the company will still face market competition and commercialization execution risks.
Over the next one and a half years, the company will continue moving into the clinical data realization stage. Each key milestone could become an important stock-price catalyst, and it will also be the core focus of market attention.
$FDMT.US

35 yuan per day,
so in a week it’s 3500 yuan, and one that has 12000 yuan
Just after graduating from university, to have such a high salary—going to the bank, you’d get $BNB $HOT

A fact you have to acknowledge
A large part of BBA’s desolation is because Huawei Aijie is too outstanding
$BNB

What kind of person is Wei Zhou?

The following information is from Doubao:

Wei Zhou (also known as Zhou Wei) left Binance in June 2021. Officially, it was claimed to be for personal reasons. However, according to information disclosed in Zhao Changpeng (CZ)’s 2026 autobiography *Freedom of Money* and subsequent reports, there were more complex internal conflicts, triggered by specific events.

1. Official statement and basic information
Resignation date: June 9–10, 2021 (reported by multiple media outlets)
Official reason: A Binance spokesperson said, “After Zhou Wei worked at Binance for 3 years, he decided to leave for personal reasons.”
Role background: Zhou Wei was Binance’s first CFO. He joined from Goldman Sachs in September 2018, bringing important institutional credibility to Binance, which had only been established for a year at the time.
Severance package: Binance repurchased his employee stock holdings for $10 million, enabling him to “leave with dignity.”

2. The real reasons: CZ’s autobiography and later reports
Core triggering event: One hour before a 2021 investment decision meeting, investment materials were revised and edited. Zhou Wei deleted key information about an investor, causing CZ to approve the investment while the资料 (materials) were incomplete.
The actual beneficiary of that investment, Rameau, was an old connection Zhou Wei had from his investment-banking days, with a direct private-interest link. If CZ had known, he would likely have vetoed the deal.
In his book, CZ described it as “crossing another line.” The relationship between the two became irreparable, and ultimately led Zhou Wei to resign voluntarily.

The disagreements that existed beforehand: Zhou Wei proposed doing proprietary trading twice, arguing that “we have all the data, so trading is easy,” but both times CZ rejected it.
There was also disagreement over the use of user data. Zhou Wei had suggested using users’ private data, but CZ refused.
Different attitudes toward the FTX investment: Zhou Wei actively pushed Binance to invest in FTX, while CZ initially did not agree.

3. Summary
The official account says Zhou Wei left Binance for personal reasons, but the real reason was a serious rift with CZ regarding investment decisions, corporate strategy, and personal integrity. The relationship ultimately broke after an incident involving the deletion of investment materials and the concealment of related-party interests. He then “left with dignity” through the company’s stock buyback.

Time goes by so fast

My brother went to karaoke with friends. After that, we also went out for dinner.

They didn’t call me for karaoke.

Now my fingers are getting blisters—he’s asking me what happened.
$BNB

Daily One Obscure U.S. Stock:
$ANAB
【Personal View】：A small-cap, game-playing type of Royalty Bio. Suitable for a light position and for an FDA catalyst setup; not recommended for a heavy, long-term hold.
Key Data:
Current price: approx. $65.43 | Total market cap: approx. $1.937 billion
Q1 collaboration revenue: $25.56 million | Cash and investments on the books: $286.5 million
30-day average daily trading volume: approx. $5.12 million | Short interest coverage: about 8 days
My reasoning:
1、The company has completed its business split; the core value has shifted to royalty cash flow. At present, its main revenue comes from GSK Jemperli royalties and the authorized collaboration for Vanda imsidolimab. As Jemperli continues to ramp up, the company’s future cash flows have some upside potential. Meanwhile, it has also launched a $100 million share repurchase program, which should provide some support to the stock price.
2、The key catalyst comes from imsidolimab.
Potential Risks:
① The company still has approximately $264 million in royalty financing liabilities; in the future, part of the Jemperli royalty cash flow will need to be prioritized to repay the Sagard financing arrangement.
② The lawsuits between the company and GSK’s Tesaro over the Jemperli licensing agreement have not yet concluded; subsequent rulings could still affect future royalty revenue.$ANAB.US

This hang-up graphic is clearly fake.
You can tell from the structure of the clothing—there are obvious signs of wearing, but the logo on the clothing shows absolutely no trace at all.
I don’t know why everyone likes looking at pictures so much. It’s all about fantasizing that by becoming A8 or A9 and becoming a big VIP, even if you look like that, you can still attract groups of beautiful women.

AI is too scary now. With just a casual touch-up of an actual photo, it can be made to look indistinguishable from the real thing.
I’m even more convinced by the argument for encryption and the proof of non-fungibility.
Attached are other imagined VIP pictures from other exchanges

Is Xiaomi’s new car so competitive?
You can drive it home for just 500 a month?

They say this is the standard accessory for middle-aged women

Fighting back and forth, and in the end the United States paid reparations

Iran made a sacrifice to get back thirty billion dollars

Men's purchasing power is lower than women's.

Even if you’re just buying a robot,

the male version is 110,000 yen more expensive than the female version.

Do girls go to the gym?
Is it working out for one minute?
Check in for ten minutes
and go home

I know I lost the bet.
I also know that U no longer belongs to me.
But when Binance sends another message reminding me,
it’s like salt being rubbed into my wound—
making me click to see the results. What results? The result of my losing?
🤡

Suddenly gave me a bright youthful feeling

This is too college-student-like